Regencell Bioscience Holdings Limited
RGC
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $3.2B
$6.48
▲ +2.69%
P/E
—
Mkt Cap
$3.2B
52-Wk Range
$4.51–$69.00
52-Week Range
$4.51 - $69.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 49.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
No forward estimates available
Value
Valuation data unavailable
Momentum
Falling
-70.8% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying RGC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
Earnings recap unavailable for this period.
Reported EPS · last 4Q
No quarterly earnings data on file.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How RGC stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.